PubRank

Ronald J Ellis

Author PubWeight™ 132.25‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2010 7.56
2 Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008 6.91
3 Enhancing antiretroviral therapy for human immunodeficiency virus cognitive disorders. Ann Neurol 2004 3.12
4 Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009 2.88
5 Soluble CD163 made by monocyte/macrophages is a novel marker of HIV activity in early and chronic infection prior to and after anti-retroviral therapy. J Infect Dis 2011 2.44
6 Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005 2.34
7 Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007 2.27
8 Neurologic complications of HIV disease and their treatment. Top HIV Med 2010 2.14
9 Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS 2006 2.13
10 Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007 2.09
11 Neuropathologic confirmation of definitional criteria for human immunodeficiency virus-associated neurocognitive disorders. J Neurovirol 2007 2.03
12 Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 2002 1.78
13 Normative data and validation of a regression based summary score for assessing meaningful neuropsychological change. J Clin Exp Neuropsychol 2011 1.73
14 Elevated sCD163 in plasma but not cerebrospinal fluid is a marker of neurocognitive impairment in HIV infection. AIDS 2013 1.71
15 Correlation of in vivo neuroimaging abnormalities with postmortem human immunodeficiency virus encephalitis and dendritic loss. Arch Neurol 2004 1.65
16 Brain mitochondrial injury in human immunodeficiency virus-seropositive (HIV+) individuals taking nucleoside reverse transcriptase inhibitors. J Neurovirol 2005 1.62
17 Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain 2006 1.60
18 Clinical factors related to brain structure in HIV: the CHARTER study. J Neurovirol 2011 1.57
19 White matter tract injury and cognitive impairment in human immunodeficiency virus-infected individuals. J Neurovirol 2009 1.57
20 Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord 2007 1.56
21 The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 2005 1.55
22 Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011 1.53
23 Effects of HIV-1 infection and aging on neurobehavioral functioning: preliminary findings. AIDS 2004 1.53
24 Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS 2013 1.51
25 Regional patterns of brain metabolites in AIDS dementia complex. Neuroimage 2004 1.40
26 HIV infection and aging independently affect brain function as measured by functional magnetic resonance imaging. J Infect Dis 2010 1.40
27 Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS 2009 1.40
28 Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci 2007 1.39
29 Chemokines in cerebrospinal fluid correlate with cerebral metabolite patterns in HIV-infected individuals. J Neurovirol 2011 1.31
30 HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol 2010 1.31
31 Neurocognitive functioning in acute or early HIV infection. J Neurovirol 2010 1.27
32 HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients. AIDS 2007 1.25
33 Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion. Arch Neurol 2003 1.22
34 Altered P-glycoprotein expression in AIDS patients with HIV encephalitis. J Neuropathol Exp Neurol 2004 1.21
35 Methamphetamine use and neuropsychiatric factors are associated with antiretroviral non-adherence. AIDS Care 2012 1.21
36 Lithium improves HIV-associated neurocognitive impairment. AIDS 2006 1.16
37 Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J Acquir Immune Defic Syndr 2003 1.15
38 Relationship of antiretroviral treatment to postmortem brain tissue viral load in human immunodeficiency virus-infected patients. J Neurovirol 2006 1.14
39 Neurologic complications of HIV disease and their treatment. Top HIV Med 2009 1.13
40 A battery approach for measuring neuropsychological change. Arch Clin Neuropsychol 2005 1.11
41 Predictive validity of demographically adjusted normative standards for the HIV Dementia Scale. J Clin Exp Neuropsychol 2007 1.10
42 A neuropsychological investigation of multitasking in HIV infection: implications for everyday functioning. Neuropsychology 2011 1.09
43 HIV-infected individuals with co-occurring bipolar disorder evidence poor antiretroviral and psychiatric medication adherence. AIDS Behav 2012 1.06
44 Computerized reaction time battery versus a traditional neuropsychological battery: detecting HIV-related impairments. J Int Neuropsychol Soc 2003 1.06
45 Neurocognitive impairment in HIV-1 clade C- versus B-infected individuals in Southern Brazil. J Neurovirol 2013 1.05
46 Human immunodeficiency virus infection heightens concurrent risk of functional dependence in persons with long-term methamphetamine use. J Addict Med 2013 1.04
47 Substance use is a risk factor for neurocognitive deficits and neuropsychiatric distress in acute and early HIV infection. J Neurovirol 2012 1.03
48 The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr 2014 1.03
49 Role of metabolic syndrome components in human immunodeficiency virus-associated stroke. J Neurovirol 2009 1.01
50 Implications of apathy for everyday functioning outcomes in persons living with HIV infection. Arch Clin Neuropsychol 2012 0.99
51 Physical exercise is associated with less neurocognitive impairment among HIV-infected adults. J Neurovirol 2013 0.99
52 Osteopontin is increased in HIV-associated dementia. J Infect Dis 2008 0.98
53 Total raltegravir concentrations in cerebrospinal fluid exceed the 50-percent inhibitory concentration for wild-type HIV-1. Antimicrob Agents Chemother 2010 0.98
54 Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir. J Acquir Immune Defic Syndr 2012 0.95
55 Role of metabolic syndrome components in HIV-associated sensory neuropathy. AIDS 2009 0.95
56 Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 2007 0.94
57 Pleocytosis is associated with disruption of HIV compartmentalization between blood and cerebral spinal fluid viral populations. Virology 2008 0.94
58 Concurrent classification accuracy of the HIV dementia scale for HIV-associated neurocognitive disorders in the CHARTER Cohort. J Acquir Immune Defic Syndr 2013 0.93
59 Role of psychiatric medications as adjunct therapy in the treatment of HIV associated neurocognitive disorders. Int Rev Psychiatry 2008 0.93
60 HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS 2014 0.92
61 CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol 2004 0.92
62 Global NeuroAIDS roundtable. J Neurovirol 2013 0.92
63 The role of cohort studies in drug development: clinical evidence of antiviral activity of serotonin reuptake inhibitors and HMG-CoA reductase inhibitors in the central nervous system. J Neuroimmune Pharmacol 2007 0.91
64 Hypertriglyceridemia in combination antiretroviral-treated HIV-positive individuals: potential impact on HIV sensory polyneuropathy. AIDS 2011 0.91
65 Increases in brain white matter abnormalities and subcortical gray matter are linked to CD4 recovery in HIV infection. J Neurovirol 2013 0.91
66 Memantine for AIDS dementia complex: open-label report of ACTG 301. HIV Clin Trials 2010 0.91
67 Darunavir is predominantly unbound to protein in cerebrospinal fluid and concentrations exceed the wild-type HIV-1 median 90% inhibitory concentration. J Antimicrob Chemother 2012 0.90
68 Cerebrospinal fluid proteomics reveals potential pathogenic changes in the brains of SIV-infected monkeys. J Proteome Res 2009 0.90
69 Incidence of post-dural puncture headache in research volunteers. Headache 2011 0.90
70 HIV and chronic methamphetamine dependence affect cerebral blood flow. J Neuroimmune Pharmacol 2011 0.89
71 Health-related quality of life 'well-being' in HIV distal neuropathic pain is more strongly associated with depression severity than with pain intensity. Psychosomatics 2012 0.89
72 A pilot study of the effects of cannabis on appetite hormones in HIV-infected adult men. Brain Res 2011 0.88
73 HIV peripheral neuropathy progression: protection with glucose-lowering drugs? J Neurovirol 2012 0.86
74 Dopamine receptor D3 genetic polymorphism (rs6280TC) is associated with rates of cognitive impairment in methamphetamine-dependent men with HIV: preliminary findings. J Neurovirol 2011 0.86
75 Population pharmacokinetics of abacavir in plasma and cerebrospinal fluid. Antimicrob Agents Chemother 2005 0.86
76 Valproic acid does not affect markers of human immunodeficiency virus disease progression. J Neurovirol 2006 0.86
77 Alterations in the levels of vesicular trafficking proteins involved in HIV replication in the brains and CSF of patients with HIV-associated neurocognitive disorders. J Neuroimmune Pharmacol 2013 0.86
78 Apathy is associated with white matter abnormalities in anterior, medial brain regions in persons with HIV infection. J Clin Exp Neuropsychol 2014 0.86
79 Neurologic complications of HIV disease and their treatment. Top HIV Med 2007 0.86
80 Genetic features of cerebrospinal fluid-derived subtype B HIV-1 tat. J Neurovirol 2012 0.85
81 Mitochondrial DNA variation and HIV-associated sensory neuropathy in CHARTER. J Neurovirol 2012 0.85
82 Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Neurologic complications of HIV disease and their treatment. Top HIV Med 2008 0.84
83 Therapeutic amprenavir concentrations in cerebrospinal fluid. Antimicrob Agents Chemother 2012 0.84
84 Cognitive functioning during highly active antiretroviral therapy interruption in human immunodeficiency virus type 1 infection. J Neurovirol 2008 0.82
85 Script generation of activities of daily living in HIV-associated neurocognitive disorders. J Int Neuropsychol Soc 2011 0.81
86 HIV-associated distal neuropathic pain is associated with smaller total cerebral cortical gray matter. J Neurovirol 2014 0.81
87 Neurocognitive functioning in a Romanian cohort of young adults with parenterally-acquired HIV-infection during childhood. J Neurovirol 2014 0.81
88 Peripheral neuropathy in ART-experienced patients: prevalence and risk factors. J Neurovirol 2013 0.81
89 Higher HIV-1 genetic diversity is associated with AIDS and neuropsychological impairment. Virology 2012 0.81
90 Antiretroviral therapy reduces neurodegeneration in HIV infection. AIDS 2015 0.81
91 Effects of traumatic brain injury on cognitive functioning and cerebral metabolites in HIV-infected individuals. J Clin Exp Neuropsychol 2011 0.80
92 Neurologic complications of HIV disease and their treatments. Top HIV Med 2006 0.80
93 Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance. Virology 2009 0.79
94 The cerebrospinal fluid HIV risk score for assessing central nervous system activity in persons with HIV. Am J Epidemiol 2014 0.79
95 Cognitive changes in asymptomatic drug-naïve human immunodeficiency virus type 1 clade C infection. J Neurovirol 2008 0.78
96 Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology 2002 0.78
97 Lower than expected maraviroc concentrations in cerebrospinal fluid exceed the wild-type CC chemokine receptor 5-tropic HIV-1 50% inhibitory concentration. AIDS 2012 0.77
98 Etravirine in CSF is highly protein bound. J Antimicrob Chemother 2013 0.77
99 (1→3)-β-D-Glucan Levels Correlate With Neurocognitive Functioning in HIV-Infected Persons on Suppressive Antiretroviral Therapy: A Cohort Study. Medicine (Baltimore) 2016 0.76
100 Higher cystatin C levels are associated with neurocognitive impairment in older HIV+ adults. J Acquir Immune Defic Syndr 2016 0.75
101 Predictors of new-onset distal neuropathic pain in HIV-infected individuals in the era of combination antiretroviral therapy. Pain 2015 0.75
102 Elevated Markers of Vascular Remodeling and Arterial Stiffness Are Associated with Neurocognitive Function in Older HIV+ Adults on Suppressive Antiretroviral Therapy. J Acquir Immune Defic Syndr 2016 0.75
103 Improving detection of HIV-associated cognitive impairment: Comparison of the International HIV Dementia Scale and a Brief Screening Battery. J Acquir Immune Defic Syndr 2016 0.75
104 Can research at the end of life be a useful tool to advance HIV cure? AIDS 2017 0.75
105 Plasma soluble CD163 is associated with postmortem brain pathology in human immunodeficiency virus infection. AIDS 2017 0.75
106 Corrigendum: Circulating HIV DNA Correlates With Neurocognitive Impairment in Older HIV-infected Adults on Suppressive ART. Sci Rep 2016 0.75
107 Coagulation imbalance and neurocognitive functioning in older HIV+ adults on suppressive antiretroviral therapy. AIDS 2017 0.75
108 Personalized Risk Index for Neurocognitive Decline Among People With Well-Controlled HIV Infection. J Acquir Immune Defic Syndr 2017 0.75
109 Impact of aging on neurocognitive performance in previously antiretroviral-naïve HIV+ individuals on their first suppressive regimen. AIDS 2017 0.75